New study results for diabetic macular edema and anti-VEGF

Diabetic Macular Edema (DME) is an accumulation of fluid in the macula—part of the retina that controls our most detailed vision abilities—due to leaking blood vessels. In order to develop DME, you must first have diabetic retinopathy.

A protein called vascular endothelial growth factor (VEGF) is one reason why weak abnormal blood vessels may grow under the retina and lead to vision loss. Anti-VEGF medicines block the effects of VEGF. Blocking this protein slows the growth of the abnormal blood vessels. This can slow the vision loss linked to wet age-related macular degeneration (AMD) or diabetic macular edema.- MDA

BOSTON — Continuing anti-VEGF treatment longer than 6 months decreased the rate of chronic persistent diabetic macular edema and slowed vision loss, according to a study presented here.


At Macula 2015, Neil M. Bressler, MD, discussed a subgroup analysis of data culled from the Protocol I clinical trial.

“The question is … do you keep treating with anti-VEGF and what happens if you don’t?” Bressler said. “We didn’t in the [ trial.] The network said, ‘If you reach a point of stability by that point, stop, and only resume treatment if it starts to worsen again.’ So, we left a lot of eyes with thickening on the table.”

The analysis included 344 eyes; 318 (93%) had at least four of a maximum of six injections before week 24.

Persistent central-involved DME was detected in 117 patients (32%). Laser photocoagulation was given if DME worsened.

Eyes with persistent DME at 24 weeks were considered to have “chronic persistent DME” until they had a central subfield thickness of less than 250 µm.

Eighty percent of eyes had chronic persistent DME at 1 year, 60% at 2 years and 40% at 3 years………

Read more:

Source: Healio     Image: Eye with diabetic macular edema provided by http;//